Cardiac Amyloidosis: How Its Epidemiology is Changing.

IF 2.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart Failure Clinics Pub Date : 2024-07-01 Epub Date: 2024-10-18 DOI:10.1016/j.hfc.2024.09.003

Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, Chiara Arzilli, Alberto Giannoni, Marco Merlo, Giuseppe Limongelli, Michele Emdin

引用次数: 0

Abstract

Cardiac amyloidosis (CA) encompasses a group of disorders characterized by an abnormal accumulation of amyloid fibrils in the heart, leading to impaired cardiac function and ultimately heart failure. While the incidence of immunoglobulin light chains amyloidosis incidence seems stable at 8 to 15.2 cases per million persons (PMP)/year, the incidence and prevalence of wild type transthyretin-CA are steadily increasing, being currently estimated at 14 to 27 cases PMP/year and 30 to 170 cases PMP, respectively. This review explores the dynamic landscape of CA epidemiology and its implications for screening and management strategies.

查看原文本刊更多论文

心脏淀粉样变性：其流行病学是如何变化的。

心脏淀粉样变性（CA）包括一组以淀粉样原纤维在心脏中异常积聚为特征的疾病，导致心功能受损并最终导致心力衰竭。虽然免疫球蛋白轻链淀粉样变的发病率稳定在每百万人(PMP)/年8 - 15.2例，但野生型转甲状腺素- ca的发病率和流行率正在稳步上升，目前估计分别为14 - 27例PMP/年和30 - 170例PMP。这篇综述探讨了CA流行病学的动态景观及其对筛查和管理策略的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart Failure Clinics CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

5.40

自引率

2.90%

发文量

期刊介绍： Heart failure is quickly becoming the most pressing health problem in the United States. Heart Failure Clinics provides practical, concise and easy-to-read coverage that encompasses everything you need to know about the current literature. Topics include acute decompensated heart failure, arrhythmias and sudden cardiac death, ventricular dysfunction, comorbidities of heart failure, diastolic dysfunction, genetic evaluation, ischemic heart disease, pulmonary arterial hypertension, and surgery/transplantation.